沙美特罗替卡松气雾剂联合异丙托溴铵对哮喘-慢性阻塞性肺疾病重叠综合征患者血清CRP、IgE和EOS水平的影响  

Effect of Salmeterol and Fluticasone Propionate Aerosol combined with Ipratropium Bromide on serum levels of CRP, IgE and EOS in patients with asthma and chronic obstructive pulmonary disease overlap syndrome

作　　者：王文娟 黄礼年[1] 武静[1] 孟楠[1] WANG Wen-juan;HUANG Li-nian;WU Jing;MENG Nan(Department of Respiration,the First Affiliated Hospital of Bengbu Medical College,Anhui Province,Bengbu 233000,China)

机构地区：[1]蚌埠医学院第一附属医院呼吸科,安徽蚌埠233000

出　　处：《中国当代医药》2018年第27期117-119,共3页China Modern Medicine

摘　　要：目的分析沙美特罗替卡松气雾剂联合异丙托溴铵对哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)患者血清C反应蛋白(CRP)、免疫球蛋白E(IgE)、嗜酸粒细胞百分比(EOS)水平的影响。方法选取2016年1月～2018年1月我院收治的80例ACOS患者作为研究对象,按照随机数字表法将其分成对照组和实验组,每组40例。对照组患者选择沙美特罗替卡松气雾剂治疗,实验组患者选择沙美特罗替卡松气雾剂联合异丙托溴铵治疗。观察分析两组患者治疗前后的血清CRP、IgE、EOS水平、临床疗效和呼吸功能改善情况。结果实验组患者的临床治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。实验组患者治疗后的血清CRP、IgE、EOS水平均显著低于对照组,差异有统计学意义(P<0.05)。实验组患者治疗后的1秒用力呼吸容积(FEV1)、FEV1/用力肺活量(FVC)、FEV1预测值均显著高于对照组,差异有统计学意义(P<0.05)。结论在对ACOS患者进行治疗时,采用沙美特罗替卡松气雾剂联合异丙托溴铵治疗,能取得比较理想的效果,能显著改善患者的血清CRP、IgE、EOS水平和肺功能,值得临床推广。Objective To analyze the effect of Salmeterol and Fluticasone Propionate Aerosol and Ipratropium Bromide on serum C reactive protein （CRP）, immunoglobulin E （IgE）, the percentage of eosinophils （EOS） level in patients with asthma and chronic obstructive pulmonary disease overlap syndrome （ACOS）, Methods A Total of 80 cases of ACOS patients who treated in our hospital From January 2016 to January 2018 were selected as subjects. According to the dig- ital random method, they were randomly divided into control group and experimental group, with 40 cases in each group. The control group was treated with Salmeterol and Flutieasone Propionate Aerosol, and the experimental group was treated with Salmeterol and Fluticasone Propionate Aerosol combined with Ipratropium Bromide. The levels of serum CRP, IgE and EOS, the clinical efficacy and respiratory function improvement were observed and analyzed be- fore and after treatment. Results The total effective rate of clinical treatment in the experimental group was significant- ly higher than that in the control group, and the difference was statistically significant （P〈0.05）. The levels of serum CRP, IgE and EOS in the experimental group were significantly lower than those in the control group, the differences were statistically significant （P〈0.05）. The one second forced breathing volume （FEV1）, FEV1/foreed vital capacity （FVC）, predictive value of FEV~ after treatment were significantly higher in the experimental group than those in the control group, the differences were statistically significant （P〈0.05）. Conclusion In the treatment of ACOS patients, the treatment of Salmeterol and Flutieasone Propionate Aerosol combined with Ipratropium Bromide can achieve an ideal effect. It can significantly improve the level of serum CRP, IgE, EOS and pulmonary function, and is worthy of clinical promotion.

关 键 词：沙美特罗替卡松气雾剂 异丙托溴铵 哮喘慢性阻塞性肺疾病重叠综合征 

分 类 号：R563[医药卫生—呼吸系统]